var data={"title":"Praziquantel: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Praziquantel: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6828?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">see &quot;Praziquantel: Drug information&quot;</a> and <a href=\"topic.htm?path=praziquantel-patient-drug-information\" class=\"drug drug_patient\">see &quot;Praziquantel: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212673\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Biltricide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212674\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Biltricide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049480\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anthelmintic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049475\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">see &quot;Praziquantel: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing interval and duration highly variable dependent on condition; for 3 times daily doses, intervals of 4 to 6 hours are suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Flukes:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clonorchiasis (<i>Clonorchis sinensis</i> [Chinese liver fluke]); Opisthorchiasis (<i>Opisthorchis viverrini</i> [Southeast Asian liver fluke]): Children and Adolescents: Limited data available in children &lt;4 years of age: Oral: 25 mg/kg/dose 3 times daily for 1 to 2 days (CDC 2012; Medical Letter [Parasitic infections 2013]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fasciolopsiasis<i> (Fasciolopsis buski), </i>Heterophyiasis<i> (Heterophyes heterophyes), </i>or<i> Metagonimus yokogawai</i> (intestinal flukes);<i> Metorchis conjunctus</i> (North American liver fluke): Limited data available: Children and Adolescents: Oral: 25 mg/kg/dose 3 times daily for 1 day (Medical Letter [Parasitic infections 2013]; <i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nanophyetus salmincola:</i> Limited data available: Children and Adolescents: Oral: 20 mg/kg/dose 3 times daily for 1 day (Medical Letter [Parasitic infections 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Paragonimiasis<i> (Paragonimus </i>spp. [lung fluke]): Children and Adolescents: Oral: 25 mg/kg/dose 3 times daily for 2 days (<i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schistosomiasis (Bilharziasis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. japonicum, S. mekongi</i>: Limited data available in children &lt;4 years of age: Children and Adolescents: Oral: 20 mg/kg/dose 3 times daily for 1 day (Medical Letter [Parasitic infections 2013]; <i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. mansoni, S. haematobium</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;5 months and Children &lt;4 years: Limited data available: Oral: 40 mg/kg/<b>day</b> divided into 1 to 2 doses for 1 day (Medical Letter [Parasitic infections 2013]; <i>Red Book </i>[AAP 2015]; Sousa-Figueiredo 2012; Wami 2016); a single dose of 40 mg/kg has been successfully used to treat urogenital <i>S. haematobium </i>in children 1 to 10 years of age and<i> S. mansoni </i>in population that included infants (age range: 5 months to 7 years); however, data suggests a lower cure rate in infants and preschool children; one possible explanation is that higher doses may be necessary in younger patients due to pharmacokinetic/dynamic differences; in preschool children, a single dose of 60 mg/kg was successfully used in children 3 to 8 years of age in a hyperendemic area to treat <i>S. mansoni</i> (Bustinduy 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;4 years and Adolescents: 20 mg/kg/dose 2 to 3 times daily (Medical Letter [Parasitic infection 2013]); in children up to 10 years of age, large scale mass drug administration trials have shown that single doses of 40 or 60 mg/kg are also effective (Bustinduy 2016; Sousa-Figueiredo 2012; Wami 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tapeworms</b>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Diphyllobothrium latum</i> (fish), <i>Taenia saginata</i> (beef), <i>Taenia solium</i> (pork); intestinal (adult) stage: Children and Adolescents: Oral: 5 to 10 mg/kg as a single dose (Medical Letter [Parasitic infections 2013]; <i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Dipylidium caninum</i> (dog); intestinal (adult) stage: Infants &ge;6 months, Children, and Adolescents: Oral: 5 to 10 mg/kg as a single dose (Medical Letter [Parasitic infections 2013]; <i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hymenolepis nana</i> (dwarf tapeworm): Children and Adolescents: Oral: 25 mg/kg as a single dose (Medical Letter [Parasitic infections 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neurocysticercosis (<i>Taenia solium</i> [pork tapeworm]); tissue (larvae) stage: Children and Adolescents: Reported regimens variable: Oral: 50 mg/kg/day for 15 days (CDC 2017; Medical Letter [Parasitic infections 2013]); another reported regimen is: 33.3 mg/kg/dose 3 times daily for 1 day followed by 16.7 mg/kg/dose 3 times daily for 29 days (<i>Red Book </i>[AAP 2015]); <b>Note:</b> May be used in conjunction with antiseizure medication and/or corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schistosomiasis:</b> 20 mg/kg/dose 3 times daily (at 4- to 6-hour intervals) for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Clonorchiasis/opisthorchiasis:</b> 25 mg/kg/dose 3 times daily (at 4- to 6-hour intervals) for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> No dosage adjustments are recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustments in hepatic impairment:</b> Moderate to severe impairment (Child-Pugh classes B and C): Use caution; decreased metabolism may lead to higher and prolonged serum concentrations; there are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212657\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Biltricide: 600 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Biltricide: 600 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212644\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049483\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer tablets with water during meals; tablets can be halved or quartered; do not chew tablets due to bitter taste. In infants and young children (eg, &lt;24 months old) who are unable to swallow tablets, the tablets have been crushed and mixed with a spoonful of orange juice in trials (Sousa-Figueiredo 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10822185\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store below 30&deg;C (86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049482\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of all stages of schistosomiasis caused by <i>Schistosoma</i> species pathogenic to humans; treatment of clonorchiasis, opisthorchiasis (FDA approved in ages &ge;4 years and adults); has also been used in the treatment of cysticercosis and many intestinal tapeworm and trematode infections </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212706\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">May be more serious in patients with a heavy worm burden.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, headache, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distress, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal pain, anorexia, atrioventricular block, bloody diarrhea, bradycardia, cardiac arrhythmia, ectopic beats, eosinophilia, hypersensitivity, hypersensitivity reaction, myalgia, paradoxical reaction (in schistosomiasis), polyserositis, pruritus, seizure, serum sickness (in schistosomiasis; Jarisch-Herxheimer-like reaction), ventricular fibrillation,vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212661\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to praziquantel or any component of the formulation; ocular cysticercosis; concomitant administration with strong cytochrome P450 (CYP450) inducers, such as rifampin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212648\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiac abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cerebral cysticercosis: It is recommended to hospitalize patients with cerebral cysticercosis for the duration of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with moderate-to-severe hepatic impairment; reduced liver drug metabolism may result in higher and longer lasting plasma concentrations of unmetabolized praziquantel.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Schistosomiasis: Praziquantel may not be effective against migrating shistosomulae; observational data indicate that praziquantel treatment in the acute phase of the infection may not prevent progression from asymptomatic to acute shistosomiasis, or from asymptomatic/acute disease to chronic disease. In addition, use in patients with shistosomiasis may be associated with clinical deterioration such as paradoxical reactions or serum sickness Jarisch-Herxheimer-like reactions, which is a sudden inflammatory immune response likely caused by the release of shistosomal antigens. Such reactions typically occur during the acute disease phase, and may lead to life-threatening events such as respiratory failure, encephalopathy, and/or cerebral vasculitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Use not recommended in patients with a history of seizures or signs of central nervous system involvement (eg, subcutaneous nodules suggestive of cysticercosis); may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug/drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Therapeutic levels of praziquantel may not be achieved with concurrent administration of strong inducers of cytochrome P450 (eg, rifampin); concurrent use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Patient information: Patients should be instructed to not drive or operate machinery on the day of treatment and the day after treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212694\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212653\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12721&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Praziquantel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Praziquantel. Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Praziquantel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Praziquantel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212654\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10822164\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Use in pregnant women only if clearly needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51093737\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests; monitor patients with cardiac irregularities during treatment; monitor for seizures; culture urine or feces for ova prior to instituting therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212647\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Increases the cell permeability to calcium in schistosomes, causing strong contractions and paralysis of worm musculature leading to detachment of suckers from the blood vessel walls and to dislodgment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212660\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 80% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: CSF concentration is 14% to 20% of plasma concentration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~80% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive first-pass effect; metabolized by the liver to hydroxylated and conjugated metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: 0.8 to 1.5 hours; Metabolites: 4.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine ~80% (&gt;99% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212663\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Biltricide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (6): $597.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212664\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biltricide (AE, AU, BB, BF, BH, BJ, CI, CY, CZ, DE, EG, ET, FR, GH, GM, GN, GR, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Cesol (DE, MX, PL);</li>\n      <li>Cisticid (BR, CL, MX, PE, VE);</li>\n      <li>Cysticide (IN);</li>\n      <li>Distocide (AE, BH, CY, EG, IL, IN, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SG, SY, VN, YE);</li>\n      <li>Droncit Vet (NO);</li>\n      <li>Fluxide (PH);</li>\n      <li>Kalcide (TW);</li>\n      <li>Opticide (TH);</li>\n      <li>Prasikon (TH);</li>\n      <li>Prazine (IN);</li>\n      <li>Praziquin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Prazite (TH);</li>\n      <li>Prazitral (AR);</li>\n      <li>Vermaqpharma Vet (NO);</li>\n      <li>Wormicide (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC, et al. Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. <i>MBio</i>. 2016;7(4). pii: e00227-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/praziquantel-pediatric-drug-information/abstract-text/27507822/pubmed\" target=\"_blank\" id=\"27507822\">27507822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Parasites - Cysticercosis. Centers for Disease Control and Prevention website. <a href=\"https://www.cdc.gov/parasites/cysticercosis/health_professionals/index.html\" target=\"_blank\">https://www.cdc.gov/parasites/cysticercosis/health_professionals/index.html</a>. Updated November 6, 2017. Accessed February 8, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Parasites - Opisthorchis Infection. Centers for Disease Control and Prevention website. <a href=\"https://www.cdc.gov/parasites/opisthorchis/health_professionals/index.html\" target=\"_blank\">https://www.cdc.gov/parasites/opisthorchis/health_professionals/index.html</a>. Updated January 10, 2012. Accessed February 8, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drugs for parasitic infections. <i>Med Lett Drugs Ther</i>. 2013;11(suppl):e1-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CH and Mahmoud AA, &ldquo;Drug Five Years Later: Praziquantel,&rdquo; <i>Ann Intern Med</i>, 1989, 110(4):290-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/praziquantel-pediatric-drug-information/abstract-text/2643915 /pubmed\" target=\"_blank\" id=\"2643915 \">2643915 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu LX and Weller PF, &ldquo;Antiparasitic Drug,&rdquo; <i>N Engl J Med</i>, 1996, 334(18):1178-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/praziquantel-pediatric-drug-information/abstract-text/ 8602186 /pubmed\" target=\"_blank\" id=\" 8602186 \"> 8602186 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sousa-Figueiredo JC, Betson M, Atuhaire A, et al. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. <i>PLoS Negl Trop Dis</i>. 2012;6(10):e1864.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/praziquantel-pediatric-drug-information/abstract-text/23094120/pubmed\" target=\"_blank\" id=\"23094120\">23094120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wami WM, Nausch N, Midzi N, et al. Comparative assessment of health benefits of praziquantel treatment of urogenital schistosomiasis in preschool and primary school-aged children. <i>Biomed Res Int</i>. 2016:9162631.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/praziquantel-pediatric-drug-information/abstract-text/27631011/pubmed\" target=\"_blank\" id=\"27631011\">27631011</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12721 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F212673\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F212674\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049480\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049475\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212657\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F212644\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049483\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10822185\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049482\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F212706\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212661\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212648\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F212694\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212653\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F212654\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10822164\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F51093737\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F212647\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F212660\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F212663\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F212664\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12721|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel: Drug information</a></li><li><a href=\"topic.htm?path=praziquantel-patient-drug-information\" class=\"drug drug_patient\">Praziquantel: Patient drug information</a></li></ul></div></div>","javascript":null}